Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 33,830 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 33,830 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $77.86 on Friday. Dianthus Therapeutics, Inc. has a one year low of $13.36 and a one year high of $88.02. The firm has a market cap of $3.46 billion, a PE ratio of -18.99 and a beta of 1.56. The firm’s 50 day moving average price is $52.53 and its 200-day moving average price is $42.56.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. Equities research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Key Headlines Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DNTH. Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $27,000. Parkside Financial Bank & Trust increased its stake in Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $40,000. Russell Investments Group Ltd. acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth about $64,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares during the period. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DNTH has been the subject of a number of recent analyst reports. Truist Financial raised their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Robert W. Baird increased their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the company a “buy” rating in a research note on Monday. Finally, HC Wainwright upped their price objective on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $115.33.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.